Repare Therapeutics

REPARE THERAPEUTICS INC

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Bets On Baidu As Chinese AI Buzz Intensifies, Ark Loads Up On $12.4 Million Worth Of Stock

Equities

News

Markets

Tech

ETFs

AMZN

ARKF

ARKK

ARKQ

ARKW

BEAM

COIN

CRSP

MELI

PATH

RBLX

RPTX

Cathie Wood&#39;s Ark Invest Loads Up On Amazon Amid Over 20% Decline In A Year: Offloads UiPath, Roblox

Cathie Wood Defies CoreWeave IPO Slump, Ark Snaps Up $3.6 Million Worth Of Stock In Nvidia-Backed Company

GTLB

HOOD

On Thursday, April 3, 2025, Cathie Wood-led Ark Invest purchased Robinhood stock worth $1.39 million amid a broader market slump.

Cathie Wood Doubles Down: Mops Up Another $1.39 Million Worth Of Robinhood Stock Amid Trump Tariff Dip

Other Key Trades

ARKG

CRWV

GENI

ROKU

SPOT

Cathie Wood-led Ark Invest made substantial trades, buying Robinhood and CoreWeave shares and selling Roblox, Genius Sports, Roku, and Spotify shares.

Cathie Wood&#39;s Ark Invest Loads Up On Robinhood, Nvidia-Backed CoreWeave: Offloads Spotify, Roku

Repare Therapeutics Inc

Press Releases

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

CRGX

IMRX

ONCY

RNXT

TSX:ONC

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Agenus

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

CytomX Therapeutics

Cue Biopharma

Fortress Biotech

Gain Therapeutics

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Kronos Bio

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Skye Bioscience

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

HC Wainwright & Co.

Stifel

Piper Sandler

Morgan Stanley

Comments

Repare Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga